Literature DB >> 28869158

Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice.

Theresa Bucsics1, Maria Schoder2, Nicolas Goeschl1, Philipp Schwabl1, Mattias Mandorfer1, Magdalena Diermayr1, Maria Feldner1, Florian Riedl1, David Bauer1, Bernhard Angermayr3, Manfred Cejna4, Arnulf Ferlitsch1, Wolfgang Sieghart1, Michael Trauner3, Markus Peck-Radosavljevic1, Josef Karner5, Franz Karnel6, Thomas Reiberger7.   

Abstract

BACKGROUND: Early implantation (<72h) of a transjugular intrahepatic portosystemic shunt (TIPS) after acute variceal bleeding (AVB) improves survival in highly selected patients.
METHODS: We retrospectively assessed bleeding control and survival of unselected cirrhotic patients undergoing early TIPS implantation within 72h. We compared the outcomes to patients meeting early TIPS criteria but receiving late TIPS within 3-28days after AVB and endoscopic/medical treatment.
RESULTS: Forty-nine patients were included. Mean MELD was 14.4 (±4.4). Thirteen patients (26.5%) presented characteristics that were exclusion criteria in previous early TIPS trials (age>75, CPS>13, HCC>Milan, previous beta-blocker/band-ligation, renal insufficiency). Bare metal and PTFE-covered stents were used in n=32 (65.3%) and n=17 (34.7%) patients, respectively, and showed similar early re-bleeding rates (9.9% vs. 7.1%; p=0.6905) and bleeding-related mortality (25.0% vs. 23.5%; p=0.9906). However, overall re-bleeding rate was lower with PTFE-TIPS (7.7% vs. 64.2%; p=0.0044) over a median follow-up of 18.5 months with a tendency towards improved survival (median 70.5 vs. 13.8 months; p=0.204). Additional 68 patients meeting stringent criteria but receiving late TIPS also showed a favorable bleeding-related mortality (8.8%), which was not achieved in similar n=34 patients by a medical/endoscopic strategy with bleeding-related mortality of 35.7%.
CONCLUSIONS: An early TIPS strategy using covered stents and implementation of 'stringent criteria' results in a favorable outcome in patients with acute variceal bleeding.
Copyright © 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cirrhosis; Early TIPS; Esophageal varices; Portal hypertension; Transjugular intrahepatic portosystemic shunt (TIPS); Variceal bleeding

Mesh:

Year:  2017        PMID: 28869158     DOI: 10.1016/j.dld.2017.08.002

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  9 in total

Review 1.  Emergent Transjugular Intrahepatic Portosystemic Shunt Creation in Acute Variceal Bleeding.

Authors:  Mithil B Pandhi; Andrew J Kuei; Andrew J Lipnik; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2020-03-04       Impact factor: 1.513

2.  Early transjugular intrahepatic portosystemic shunt for acute variceal bleeding: a systematic review and meta-analysis.

Authors:  Guang-Peng Zhou; Yi-Zhou Jiang; Li-Ying Sun; Zhi-Jun Zhu
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

3.  Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis.

Authors:  Theresa Bucsics; Katharina Lampichler; Constantin Vierziger; Maria Schoder; Florian Wolf; David Bauer; Benedikt Simbrunner; Lukas Hartl; Mathias Jachs; Bernhard Scheiner; Michael Trauner; Thomas Gruenberger; Franz Karnel; Mattias Mandorfer; Thomas Reiberger
Journal:  Dig Dis Sci       Date:  2022-03-17       Impact factor: 3.199

Review 4.  Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Authors:  Roberto Cannella; Lambros Tselikas; Fréderic Douane; François Cauchy; Pierre-Emmanuel Rautou; Rafael Duran; Maxime Ronot
Journal:  JHEP Rep       Date:  2022-04-04

Review 5.  Where does TIPS fit in the management of patients with cirrhosis?

Authors:  Juan Carlos García-Pagán; Saad Saffo; Mattias Mandorfer; Guadalupe Garcia-Tsao
Journal:  JHEP Rep       Date:  2020-05-23

6.  Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria.

Authors:  Nikolaus Pfisterer; Caroline Schmidbauer; Florian Riedl; Andreas Maieron; Vanessa Stadlbauer; Barbara Hennlich; Remy Schwarzer; Andreas Puespoek; Theresa Bucsics; Maria Effenberger; Simona Bota; Michael Gschwantler; Markus Peck-Radosavljevic; Mattias Mandorfer; Christian Madl; Michael Trauner; Thomas Reiberger
Journal:  Wien Klin Wochenschr       Date:  2020-12-03       Impact factor: 1.704

7.  Early-TIPS Versus Current Standard Therapy for Acute Variceal Bleeding in Cirrhosis Patients: A Systemic Review With Meta-analysis.

Authors:  Shuang Li; Chao Zhang; Lu-Lu Lin; Qi Wang; Hong-Xia Zuo; Ai-Ling Zhan; Jie Luo; Yu-Ming Niu; Guo-Qing Zhong
Journal:  Front Pharmacol       Date:  2020-05-20       Impact factor: 5.810

8.  Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease.

Authors:  Benedikt Simbrunner; Rodrig Marculescu; Bernhard Scheiner; Philipp Schwabl; Theresa Bucsics; Alexander Stadlmann; David J M Bauer; Rafael Paternostro; Ernst Eigenbauer; Matthias Pinter; Albert Friedrich Stättermayer; Michael Trauner; Mattias Mandorfer; Thomas Reiberger
Journal:  Liver Int       Date:  2020-05-18       Impact factor: 5.828

Review 9.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.